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Abstract
Background: Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of endothelial nitric
oxide synthase (eNOS) that is associated with endothelial dysfunction, and is a risk marker for
cardiovascular disease, a significant problem in Type 1 diabetes. The aim of the present study was
to measure circulating ADMA, and define its association with endothelial dysfunction and
endothelial markers in people with Type 1 diabetes with low likelihood of macrovascular disease.
Methods:  Sixty-one young people with Type 1 diabetes without macrovascular disease or
nephropathy and 62 healthy volunteers underwent brachial artery flow-mediated dilatation (FMD)
and assay of plasma ADMA and adhesion molecules.
Results: Age, gender, BMI, lipid profile and renal function were similar in the two groups. People
with Type 1 diabetes had impaired FMD compared to healthy controls (5.0 ± 0.4 vs 8.9 ± 0.4%; p
< 0.001). Plasma ADMA levels were significantly lower in the people with diabetes compared to
healthy controls (0.52 ± 0.12 vs 0.66 ± 0.20 μmol/l, p < 0.001). Plasma ICAM-1, E-selectin and PAI-
1 levels were significantly higher in people with diabetes compared to healthy controls (median 201
(IQR 172–226) vs 180 (156–216) μg/l, p = 0.027; 44.2 (32.6–60.9) vs. 33.1 (22.4–51.0) μg/l; p =
0.003 and 70.8 (33.3–85.5) vs 46.3 (23.9–76.8) μg/l, p = 0.035). Plasma ADMA and VCAM-1 levels
were positively correlated (r = 0.37, p = 0.003) in people with diabetes. There was no correlation
between the plasma ADMA and FMD.
Conclusion: ADMA levels are not associated with endothelial dysfunction in young adults with
Type 1 diabetes without microalbuminuria or known macrovascular disease. This suggests that the
impaired endothelial function in these individuals is not a result of eNOS inhibition by ADMA.
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Background
Type 1 diabetes is associated with endothelial dysfunction
and increased cardiovascular risk [1]. Endothelial nitric
oxide synthase (eNOS) converts L-Arginine to nitric oxide
(NO), which is a key mediator of vascular homeostasis
due to its central role in the maintenance of the endothe-
lial milieu. ADMA is a competitive inhibitor of eNOS,
which thus reduces the production of NO and might pos-
sibly cause endothelial dysfunction [2]. The circulating
levels of ADMA have been found to be raised in the pres-
ence of cardiovascular risk factors including hypertension,
renal dysfunction and Type 2 diabetes as well as in indi-
viduals with cardiovascular disease [3-6]. Studies which
assessed ADMA levels in people with Type 1 diabetes have
reported conflicting results [7,8].
Circulating ADMA concentration is eliminated in part by
enzymatic degradation by dimethylarginine dimethyl-
aminohydrolases (DDAH)-1 and -2, and in part by renal
excretion [9,10]. While normally DDAH activity accounts
for about 80% of total body elimination of ADMA with
renal excretion contributing only 20%, under pathophys-
iological conditions renal function may have a stronger
influence on ADMA levels [11,12]. In Type 1 diabetes this
might be true in the earlier stages when renal hyperfiltra-
tion prevails, as well as when diabetic nephropathy devel-
ops, suggesting that different stages of disease may
variably affect ADMA concentrations.
Endothelial function can be modulated by several factors
associated with diabetes including degree of acute hyper-
glycaemia, duration of diabetes, accumulation of
advanced glycosylated end products and complications
such as nephropathy and microalbuminuria [13].
Endothelial function can be assessed non-invasively by
measuring brachial artery flow-mediated dilatation
(FMD). Soluble adhesion molecules like intercellular
adhesion molecule-1 (ICAM-1), vascular cellular adhe-
sion molecule-1 (VCAM-1) and E-selectins are involved in
the recruitment of leucocytes to sites of inflammation at
the endothelium and are thus involved in the pathogene-
sis of atherosclerosis [14]. Plasma plasminogen activator
inhibitor-1 (PAI-1) is mainly produced by the endothe-
lium and is the major physiological inhibitor of tissue
type plasminogen activation. Elevated PAI-1 levels
increase the risk of atherothrombosis and may promote
the progression of vascular disease [15].
The underlying mechanism of endothelial dysfunction in
Type 1 diabetes is not fully understood. Experimental ani-
mal studies have shown that prolonged exposure to
hyperglycaemia can cause enhanced eNOS expression
with increased NO release but at the same time with an
even more profound increase in superoxide anion (O2
-)
levels [16].
The aim of the present study was to measure circulating
ADMA levels and their association with cellular adhesion
molecules, PAI-1 levels, and FMD in people with Type 1
diabetes with low likelihood of arterial wall damage.
Methods
Participants
The study population was 61 people with Type 1 diabetes
without macrovascular disease or microalbuminuria and
62 healthy volunteers, all age 16–35 years. Type 1 diabetes
required serum C-peptide <0.15 nmol/l when plasma glu-
cose >5.5 mmol/l or a history of ketoacidosis with Type 1
diabetes phenotype. All were insulin-treated and had a
duration of diabetes of >1 yr. Absence of microalbuminu-
ria was determined by measurement of urinary albu-
min:creatinine ratio (last three samples all <2.5 mg/mmol
in men, <3.5 mg/mmol in women), and of macrovascular
disease by absence of history of a cardiovascular event or
procedure, angina (Rose questionnaire), ischaemic ECG
abnormalities, use of statins or ACE inhibitors, and
abnormal pedal pulses. The participants were attending
the Newcastle Diabetes Centre for routine diabetes care.
The age-matched non-diabetic control group was
recruited from relatives, friends and contacts of the partic-
ipants and investigators, and local offices. They were also
screened to exclude the presence or possibility of arterial
disease. Local ethical committee approval was obtained
from Gateshead and South Tyneside Local Research Ethics
Committee. All participants gave written informed con-
sent to participation in the study.
Procedures
Study procedures were performed at Newcastle Diabetes
Centre, and at the Department of Medical Physics, New-
castle General Hospital. Medical examination included a
12-lead ECG, the Rose angina questionnaire, blood pres-
sure measurement whilst sitting by automatic sphyg-
momanometer (Omron, HEM-773AC, Bannokburn,
Illinois, USA), and body weight in indoor clothing with-
out shoes.
Women were studied in the first 10 days of the menstrual
cycle. All the participants attended early morning, fasting,
having avoided caffeinated beverages, cigarettes and stren-
uous exercise since the previous evening. They were given
a low-fat breakfast, informally matched to usual carbohy-
drate intake, together with usual insulin dose in those
with diabetes. The post-prandial state was chosen to avoid
the insulin-deficient state often found in people with Type
1 diabetes at the end of the night, and because of evidenceCardiovascular Diabetology 2009, 8:27 http://www.cardiab.com/content/8/1/27
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that the post-prandial state is more pathogenetically sig-
nificant for the development of vascular damage in people
with diabetes [17].
Measurements and assays
Flow-mediated dilatation (FMD)
Brachial artery FMD was measured by a trained scientist (L
Sibal) using high resolution ultrasound machine (5–12
MHz linear transducer, HDI 5000, ATL, Bothell, WA,
USA) with data acquisition by artificial neural network
software (VIA software, London, UK) imaging the vessel
wall 20 times/sec and in accordance with international
guidelines [18,19]. The brachial artery was studied 20–
100 mm proximal to the antecubital fossa in supine par-
ticipants after 15 min rest. Pressure in an upper-forearm
sphygmomanometer cuff was raised to 250 mmHg for 5
min, and FMD automatically calculated as the percentage
increase in diastolic diameter after reactive hyperaemia
55–65 seconds after deflation to baseline. After a further
15 min, 400 μg sublingual glyceryl trinitrate (GTN) was
given, and diastolic diameter remeasured after 5 min for
measurement of endothelial-independent dilatation.
Biochemical analysis
HbA1c was measured using a DCCT-aligned HPLC (Tosoh
Bioscience, Stuttgart, Germany) method (normal refer-
ence <6.1%). Serum lipids were measured by standard
enzymatic methods, with HDL cholesterol by a routine,
antibody based homogeneous method. Other biochemi-
cal analyses were measured by standard methods in the
same clinical trials accredited laboratory (Royal Victoria
Infirmary, Newcastle upon Tyne, UK). Estimated glomer-
ular filtration rate (eGFR), using the four-variable MDRD
equation was calculated [20]. Plasma plasminogen activa-
tor inhibitor-1 (PAI-1) was measured by ELISA, plasma
soluble E-selectin (E-selectin), plasma soluble intercellu-
lar adhesion molecule-1 (ICAM-1) and plasma soluble
vascular cellular adhesion molecule-1 (VCAM-1) by
immunoassay by a solid phase ELISA.
Plasma ADMA concentration was determined by an ELISA
kit (DLD Diagnostika, Hamburg, Germany) which has
recently been described and validated in detail [21]. In
brief, cross-reactivity was 1.2% for symmetric dimethyl-
arginine (SDMA) and <0.02% for L-arginine. The limit of
detection was 0.05 μmol/l. There is a good correlation of
the values measured by this ELISA and LC-tandem MS (n
= 29; r = 0.984; p < 0.0001). Reference ranges for ADMA
have been established by this technique recently [22].
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows (Statistical Package for Social Science, version 15;
Chicago, Illinois, USA). Comparisons of the groups were
examined by Student's t test for normally distributed data,
Mann Whitney U test for nonparametric data and Chi
square test for categorical variables. Pearson and Spear-
man correlation coefficients were used to determine the
relationships between continuous variables. Stepwise
regression analysis was performed to assess predictors of
ADMA levels adjusted for gender and smoking and
including all variables with a p < 0.10. A p value of <0.05
was considered statistically significant for all analyses.
Results
The characteristics of the participants are shown in Table
1. The mean duration of diabetes was 11.4 ± 6.6 years. The
fasting plasma glucose level was 10.0 ± 4.6 mmol/l and
the HbA1c 8.5 ± 1.7% in the people with diabetes, statisti-
cally higher than the healthy controls as expected. The
lipid profile and the renal functions were not statistically
significantly different in the two groups (Table 1).
Soluble endothelial markers and ADMA levels
Plasma ADMA levels were significantly lower in people
with diabetes compared to healthy controls (0.52 ± 0.02
vs 0.66 ± 0.03 μmol/l, p < 0.001) (Table 2). The ADMA
levels were comparable amongst the smokers and non-
smokers in people with diabetes (0.52 ± 0.03 vs 0.51 ±
0.02 μmol/l, p = 0.868). Furthermore, ADMA levels were
comparable in men and women with diabetes (0.52 ±
0.02 vs 0.52 ± 0.02 μmol/l, p = 0.967).
The plasma ICAM-1 levels were significantly higher in
people with diabetes compared to healthy controls
(median 201 (IQR 172–226) vs 180 (156–216) μg/l, p =
0.027). Plasma PAI-1 levels were significantly higher in
the people with diabetes compared to healthy controls
(70.8 (33.3–85.5) vs 46.3 (23.9–76.8) μg/l, p = 0.035).
Plasma VCAM-1 levels were comparable between the two
groups (550 (477–666) vs 551 (472–631) μg/l, p = 0.395)
(Table 2).
In people with diabetes, the plasma PAI-1 levels were pos-
itively correlated with serum total cholesterol levels (r =
0.41, p = 0.001), LDL cholesterol (r = 0.266, p = 0.045),
triglyceride (r = 0.35, p = 0.006), and with HbA1c(r = 0.38,
p = 0.003). In people with diabetes, plasma ADMA and
VCAM-1 levels were positively correlated (r = 0.37, p =
0.003) (Figure 1). Stepwise regression analysis showed
that ADMA was independently predicted by VCAM-1
(standardized beta coefficient 0.40, p = 0.002). Other rela-
tionships were not statistically significant.
Endothelial function
In people with diabetes FMD was significantly impaired
compared to healthy controls (5.0 ± 0.4 vs 8.9 ± 0.4%, p
< 0.001). Brachial artery vasodilatation in response to
GTN was significantly impaired in people with diabetes
compared to the healthy controls (16.1 ± 0.8 vs 24.1 ±Cardiovascular Diabetology 2009, 8:27 http://www.cardiab.com/content/8/1/27
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1.0%, p < 0.001). There was no correlation between the
plasma ADMA levels and the endothelial function.
Discussion
Type 1 diabetes is associated with increased cardiovascu-
lar disease and mortality. Endothelial dysfunction is an
early feature in the development of vascular complica-
tions in people with diabetes [1]. The present study has
found impaired endothelial function, decreased ADMA
levels and increased soluble endothelial markers and PAI-
1 levels in people with Type 1 diabetes without any evi-
dence of macrovascular complications or microalbu-
minuria. Our study is consistent with previous studies
[8,23] which showed reduced levels of ADMA in individ-
uals with Type 1 and Type 2 diabetes, whilst contrasting
with the results of another study reporting higher levels in
people with Type 1 diabetes compared to healthy individ-
uals [7].
Hyperglycaemia is associated with endothelial dysfunc-
tion both in-vivo [24] and in-vitro [16]. The underlying
mechanism of endothelial dysfunction in Type 1 diabetes
is not fully understood. Reduced NO levels seem to play a
central role in the development of endothelial dysfunc-
Table 1: Characteristics of the people with Type 1 diabetes and the healthy control group studied
Type 1 diabetes Healthy controls p
n 61 62
Age (yr) 25.2 ± 5.2 24.6 ± 4.7 0.459
Duration of diabetes (yr) 11.4 ± 6.6 -
Sex (M/F) 39/35 36/44 0.339
Smoking (n (%)) 18 (24) 11 (14) 0.094
BMI (kg/m2) 25.1 ± 3.4 24.9 ± 4.2 0.739
Waist-hip ratio 0.89 ± 0.07 0.87 ± 0.06 0.256
Systolic BP (mmHg) 120 ± 12 120 ± 10 0.957
Diastolic BP (mmHg) 71 ± 8 72 ± 10 0.625
HbA1c (%) 8.6 ± 1.6 5.2 ± 0.3 <0.001
Fasting plasma glucose (mmol/l) 10.2 ± 4.8 4.8 ± 0.5 <0.001
Post-prandial glucose (mmol/l) 11.2 ± 5.6 4.5 ± 0.8 <0.001
Serum cholesterol (mmol/l) 4.8 ± 0.9 4.5 ± 0.9 0.182
Serum HDL cholesterol (mmol/l) 1.5 ± 0.3 1.5 ± 0.4 0.967
Serum triglyceride (mmol/l) 0.9 (0.7–1.4) 0.9 (0.7–1.3) 0.451
LDL cholesterol (mmol/l) 2.7 ± 0.8 2.6 ± 0.7 0.330
Serum creatinine (μmol/l) 86 ± 13 83 ± 13 0.254
Estimated glomerular filtration rate (eGFR) (ml/min/1.73-m2) 90.3 ± 13.7 86.3 ± 15.6 0.263
Medications (n (%))
Metformin 1 (1) 0 (0)
Thyroxine 5 (7) 0 (0)
Oral contraceptives 5 (7) 1 (1)
Antidepressants 2 (3) 0 (0)
Multivitamins 3 (4) 9 (11)
Inhalers 0 (0) 6 (8)
Mean ± SD; Median (IQR); or n(%)
To convert values for glucose to milligrams per decilitre, multiply by 18.01. To convert values for cholesterol to milligrams per decilitre, multiply by 
38.67. To convert values for triglycerides to milligrams per decilitre, multiply by 88.57. To convert values for creatinine to milligrams per decilitre, 
multiply by 0.011.
Table 2: Measures of endothelial function, ultrasonographic measures, and circulating markers of endothelial dysfunction in people 
with Type 1 diabetes and healthy controls
Type 1 diabetes Healthy controls p
ADMA (μmol/l) 0.52 ± 0.02 0.66 ± 0.03 <0.001
ICAM-1 (μg/l) 201.3 (171.7–226.4) 179.5 (156.4–216.3) 0.027
VCAM-1 (μg/l) 549.9 (477.2–666.2) 550.5 (471.6–631.3) 0.395
E-Selectin (μg/l) 44.2 (32.6–60.9) 33.1 (22.4–51.0) 0.003
PAI-1 (μg/l) 70.8 (33.3–85.5) 46.3 (23.9–76.8) 0.035
FMD (%) 5.0 ± 0.4 8.9 ± 0.4 <0.001
GTN (%) 16.1 ± 0.8 24.1 ± 1.0 <0.001
Mean ± SE; Median (IQR)Cardiovascular Diabetology 2009, 8:27 http://www.cardiab.com/content/8/1/27
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tion amongst the multiple pathogenetic mechanisms that
have been postulated. NO levels might be reduced as a
result of a combination of decreased NO production
because of decreased activity and/or reduced expression of
eNOS, or decreased activity of NO, or its increased degra-
dation by reactive oxygen species or increased production
of superoxide ions. A weakness of our study is then that
we did not make any measure of oxidative stress.
ADMA has emerged as an independent predictor of cardi-
ovascular risk and is increased in people with risk factors
for cardiovascular disease [6]. Studies of ADMA in people
with diabetes report conflicting results [7,23]. Our study
has shown significantly lower levels of ADMA in people
with Type 1 diabetes compared to healthy individuals and
a lack of association between endothelial function and
ADMA. This probably suggests that the endothelial dys-
function in these individuals is not necessarily due to
decreased NO production because of eNOS inhibition by
ADMA.
The finding of lower ADMA levels in Type 1 diabetes in
our study is consistent with a previous study in children
with uncomplicated Type 1 diabetes [8]. Lower levels of
ADMA were reported in people with Type 2 diabetes and
the ADMA levels were associated with glomerular filtra-
tion rate (GFR) but not with risk factors of vasculopathy
[23]. We also did not find any association between
endothelial function or risk factors for CVD and plasma
ADMA levels in the individuals with diabetes. Paiva and
colleagues suggested that the lower level of ADMA in dia-
betic people with no complications could be because of
possibly increased excretion of ADMA due to hyperfiltra-
tion [23]. Renal vasodilatation and hyperfiltration has
been shown in experimental diabetes and in people with
early diabetic nephropathy and microalbuminuria [25].
Furthermore, ADMA has been shown to accumulate in
people with chronic renal failure [4].
Although there was a trend for eGFR to be higher in peo-
ple with diabetes than in the healthy people, this differ-
ence was not statistically significant. Circulating ADMA
concentration is regulated by an interplay between its gen-
eration during the hydrolytic breakdown of methylated
proteins, enzymatic degradation to L-citrulline and
dimethylamine by dimethylarginine dimethylaminohy-
drolases (DDAH)-1 and -2, and renal excretion [9,10,26].
While normally, DDAH activity accounts for about 80%
of total body elimination of ADMA, it is possible that dis-
turbance of GFR by hyperglycaemia could be a factor in
lowering ADMA levels. Hyperglycaemia may also directly
influence ADMA levels through unknown mechanisms by
influencing either the production of ADMA or its metab-
olism by DDAH.
The results of this present study are in contrast to the study
published by Altinova and colleagues who showed
plasma ADMA levels to be significantly higher in people
with uncomplicated Type 1 diabetes [7]. Notably, the
ADMA levels (by HPLC technique) in that study (7) were
almost five-to nine-fold higher in the people with diabe-
tes compared to the levels reported in the present study
(by ELISA) and by other research groups(HPLC) [23].
However, eGFR was not reported in that study (7). It can
be speculated that the higher ADMA in that study could
possibly be due to a relatively reduced eGFR in the people
with diabetes, though this could be attributed to the dif-
ferent assay technique used. Elevated plasma ADMA levels
have been shown to be increased in patients with early
diabetic nephropathy which in turn confer increased car-
diovascular morbidity [27].
Experimental studies have demonstrated that hypergly-
caemia leads to upregulation of eNOS causing increased
production of NO by 30–40% in cultured endothelial
cells, whilst increasing the superoxide anion production
drastically by almost 300% [16]. Interestingly, in vivo
studies in streptozotocin- induced diabetic rats have
shown up-regulation of eNOS, marked reduction of vas-
cular NO bioavailability as well as endothelial dysfunc-
tion [28]. The up-regulated eNOS system can get
uncoupled leading to superoxide production rather than
NO production. Endothelial NOS (eNOS) enzymatic
activity is regulated, amongst other factors, by the availa-
bility of co-factor tetrahydrobiopterin (BH4). Diabetes
mellitus is associated with decreased BH4 levels and this
can lead to uncoupling of eNOS and result in production
of superoxide rather than NO [29]. Experimental studies
have shown that overexpression of eNOS accelerates
Relationship between plasma ADMA and VCAM-1 levels in  people with Type 1 diabetes (r = 0.37, p = 0.003) Figure 1
Relationship between plasma ADMA and VCAM-1 
levels in people with Type 1 diabetes (r = 0.37, p = 
0.003).
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atherosclerotic lesion formation in apolipoprotein E-defi-
cient mice lacking sufficient BH4 [30]. In a study in peo-
ple with hypertension, Dixon and colleagues suggested
that eNOS is present in the uncoupled state in people who
have coexisting hypertension and diabetes, thus contrib-
uting to significantly increased superoxide levels [31]. As
ADMA is a competitive inhibitor of eNOS, it may be pos-
sible that the decreased ADMA levels in people with
uncomplicated Type 1 diabetes might be detrimental to
the vascular milieu in these people as this may further
facilitate eNOS overexpression and increased superoxide
production and cardiovascular risk.
Intercellular adhesion molecule-1 (ICAM-1), E-selectin
and PAI-1 levels were significantly increased in the dia-
betic people and are consistent with previous studies
[32,33]. We noted a positive correlation between the PAI-
1 levels and the traditional risk factors of increased cardi-
ovascular risk. In a recent study PAI-1 levels independ-
ently related to coronary artery calcium, a surrogate for
subclinical CVD, in young people with Type 1 diabetes
[34]. Plasma ICAM-1 levels have been shown to be associ-
ated with several established cardiovascular risk factors
[14,35]. We found a positive correlation between plasma
VCAM-1 levels and the plasma ADMA levels. Increased
ADMA levels have been shown to increase mononuclear
cell adhesiveness in hypercholesterolaemic patients [36],
an effect that may be mediated by enhanced endothelial
expression of VCAM-1 and other adhesion proteins [37].
Conclusion
In summary, our study has shown that people with Type
1 diabetes uncomplicated with microalbuminuria or mac-
rovascular disease have impaired endothelial function
although with lower levels of ADMA. This is associated
with increased soluble endothelial markers and PAI-1 lev-
els thus providing a milieu for increased thrombovascular
disease. Further studies are required to elucidate the role
of ADMA in endothelial dysfunction in people with Type
1 diabetes.
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